Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma-Reference-Cited by-同舟云学术

Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma

Published:2022-09-19 Issue:1 Volume:27 Page:1110-1121
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Zuo Xiaojia¹²³,Liu Dingsheng¹

Affiliation:

1. Department of Hematology, Shanghai Gongli Hospital, The Second Military Medical University, Shanghai, People’s Republic of China

2. Department of Oncology and Hematology, Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai, People’s Republic of China

3. Guizhou Medical University, Guiyang, People’s Republic of China

Funder

Discipline Construction Program of Pudong New District Health Bureau of Shanghai

Publisher

Informa UK Limited

Subject

Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2022.2124694

Reference128 articles.

1. Multiple myeloma

2. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy

3. Multiple myeloma

4. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma

5. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma;Cancers;2024-03-28

2. DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance;Nature Communications;2024-01-04

3. Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settings;2023-04-09

4. Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms;Frontiers in Immunology;2022-10-12